Crizotinib Cas 877399-52-5

CAS 877399-52-5 API Raw Materials For Medicines Crizotinib Agents Fast Acting Crizotinib Powder Specification Crizotinib Drug Description Crizotinib (trade name Xalkori, [1] Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor,...
Product Details

CAS 877399-52-5 API Raw Materials For Medicines Crizotinib Agents Fast Acting


 Crizotinib Powder Specification

Name: Crizotinib

CAS No.

877399-52-5

Content

98.5-101.5%

Appearance

White Crystalline Powder

Formula

C21H22Cl2FN5O

Molecular Weight

450.3367

Moisture

≤0.1%

Loss on Drying

≤0.2%

Residue on ignition

≤0.1%

Density

1.475g/cm3

Boiling point

599.177°C at 760 mmHg

Flash(ing) point

316.171°C

Heavy Metals

≤10PPM

Acidity or Alkalinity

Conform

Chloride

Conform

Readily Carbonizable Substances

Conform

Ordinary Impurities

Conform


 Crizotinib Drug Description
 Crizotinib (trade name Xalkori, [1] Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
 
 Crizotinib Drug Application
 ALK mutations are thought to be important in driving the malignant phenotype in about 15% of cases of neuroblastoma, a rare form of peripheral nervous system cancer that occurs almost exclusively in very young children.
 
Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.

Clinical trials
 Crizotinib caused tumors to shrink or stabilize in 90% of 82 patients carrying the ALK fusion gene. Tumors shrank at least 30% in 57% of people treated. Most had adenocarcinoma, and had never smoked or were former smokers. They had undergone treatment with an average of three other drugs prior to receiving crizotinib, and only 10% were expected to respond to standard therapy. They were given 250 mg crizotinib twice daily for a median duration of six months. Approximately 50% of these patients suffered at least one side effect, such as nausea, vomiting, or diarrhea. Some responses to crizotinib have lasted up to 15 months.

A phase 3 trial, PROFILE 1007,[18] compares crizotinib to standard second line chemotherapy (pemetrexed or taxotere) in the treatment of ALK-positive NSCLC. Additionally, a phase 2 trial, PROFILE 1005, studies patients meeting similar criteria who have received more than one line of prior chemotherapy.
 Crizotinib is also being tested in clinical trials of advanced disseminated anaplastic large-cell lymphoma, and neuroblastoma.

Competitive Advantage
 First----Good quality
 All steroids are produced under GMP conditions according to Standard Operation 1. Procedure(SOP), not from little underground labs or black markets, so the quality is guaranteed.
 
 Second---Discreet packing methods
 For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels.
 
 Third--99.99% customs clearance rate
 We have rich experience in shipping parcel to USA, Australia, UK, Canada, Brazil, Russia, Germany, Poland, Mexico, etc.
 
 Forth---Injectable steroid
 We offer melting powder into liquid service. And ship the liquid in special bottles. 1. Good quality. All products are produced under GMP conditions according to Standard Operation Procedure(SOP), not from little underground labs or black markets, so the quality is guaranteed.
 We offer melting powder into liquid service.


Hot Tags: crizotinib cas 877399-52-5, China, suppliers, wholesale, buy
Feedback